Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of the Safety, Tolerability, and Effectiveness of Halo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent~2. Ages between 18-45 years, inclusive~3. Non-tobacco/nicotine use (at least 3 months)~4. BMI of 17-35 kg/m2 inclusive~5. Able to comply with all study procedures and follow-up~6. Healthy on the basis of screening medical exam, blood chemistries, hematology, and serum pregnancy tests for females (at screening )~7. Non-pregnant or breast-feeding~Exclusion Criteria:~1. History of current use of narcotics, or recreational drug use.~2. Use of \> 7 alcoholic beverages in 1 week~3. Any acute illness such as asthma, cardiovascular, respiratory, hepatic, renal, hematologic, gastrointestinal (including eating disorder), endocrine/metabolic, neurologic, dermatologic, or psychiatric disease.~4. Treatment with another investigational product in the past 30 days~5. Immunocompromised status including HIV by history~6. Use of any other intra-oral product (especially antiseptic).~7. Intended use of mouthwash during study duration~8. Laboratory (screening) of creatinine \> 1.5 X ULN, hemoglobin \< 10.5 g/dL, platelet count ≤ 99,000/mm3, absolute neutrophil count ≤1200/ mm3, serum glucose ≥ 150 mg/dl (Subject can enroll prior to receiving lab results. Subject will be contacted if lab results are an exclusion and discontinue from study)~9. Use of any systemic antibiotic or antifungal within 30 days of screening~10. Prior or current history of seasonal allergies, chronic sinusitis or rhinitis~11. Allergy to any component of Halo~12. Oral lesions~13. Dentures~14. Dental Treatment currently in progress (implants, root canals, complex restorative procedures)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Halo Oral Spray (Type: EXPERIMENTAL): Based upon the preliminary studies that assessed the duration of the antimicrobial effects of Halo as reported in the preliminary studies and feasibility, subjects assigned to both study arms will be asked to spray the product intra-orally 3 times daily (Three sprays per use, total = 9 sprays per day).
- Halo Placebo (Type: PLACEBO_COMPARATOR): The placebo will consist of purified sterile water without CPC - the active antiseptic. Subjects assigned to both study arms will be asked to spray the product intra-orally 3 times daily (Three sprays per use, total = 9 sprays per day).

Based on this trial design, predict the completion outcome and termination type (if applicable).